Phase 2 Metastatic Solid Tumor trials recruiting now
All Metastatic Solid Tumor trials, every phase
8
Phase 2 recruiting
Other phases for Metastatic Solid Tumor
Phase 2 Metastatic Solid Tumor trials
- A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
- A Study of IDP-001 in Advanced or Metastatic Solid Tumors
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
- GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Common questions
What does Phase 2 mean?
Is this list complete?
No. For the full record, search ClinicalTrials.gov.